An update on emerging drugs for the treatment of erectile dysfunction

References

• Gofrit ON. The evolutionary role of erectile dysfunction. Med Hypotheses. 2006;67:1245–1249.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83–90.
   PubMed Web of Science ®Google Scholar
• Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the massachusetts male aging study. J Urol. 1994;151:54–61.
   PubMed Web of Science ®Google Scholar
• Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–56.
   PubMed Web of Science ®Google Scholar
• Saigal CS, Sifakis F, Montes de Oca R, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006;166:207.
   PubMed Web of Science ®Google Scholar
• Peak TC, Yafi FA, Sangkum P, et al. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015;20:263–275.
   PubMed Web of Science ®Google Scholar
• Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12:305–311.
   PubMed Web of Science ®Google Scholar
• Russo GI, Milenkovic U, Hellstrom W, et al. Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: a systematic review of the literature. Eur Urol. 2018. DOI:10.1016/j.eururo.2018.07.005
   Web of Science ®Google Scholar
• Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the massachusetts male aging study. Psychosom Med. 1998;60:458–465.
   PubMed Web of Science ®Google Scholar
• Mak R, De Backer G, Kornitzer M, et al. Prevalence and correlates of erectile dysfunction in a population-based study in Belgium. Eur Urol. 2002;41:132–138.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang Y, Wang J, et al. Erectile dysfunction and depression: a systematic review and meta-analysis. J Sex Med. 2018;15:1073–1082.
   PubMed Web of Science ®Google Scholar
• McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man’s inability to have sex? J Sex Med. 2014;11:347–363.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009;29:157–164.
   PubMed Web of Science ®Google Scholar
• Corona G, Ricca V, Bandini E, et al. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med. 2009;6:1259–1269.
   PubMed Web of Science ®Google Scholar
• Chambers SK, Chung E, Wittert G, et al. Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment. Transl Androl Urol. 2017;6:60–68.
   PubMed Web of Science ®Google Scholar
• Rivers BM, August EM, Gwede CK, et al. Psychosocial issues related to sexual functioning among African-American prostate cancer survivors and their spouses. Psychooncology. 2011;20:106–110.
   PubMed Web of Science ®Google Scholar
• Wittmann D, Carolan M, Given B, et al. What couples say about their recovery of sexual intimacy after prostatectomy: toward the development of a conceptual model of couples’ sexual recovery after surgery for prostate cancer. J Sex Med. 2015;12:494–504.
   PubMed Web of Science ®Google Scholar
• Hamilton K, Chambers SK, Legg M, et al. Sexuality and exercise in men undergoing androgen deprivation therapy for prostate cancer. Support Care Cancer. 2015;23:133–142.
   PubMed Web of Science ®Google Scholar
• Maliski SL, Rivera S, Connor S, et al. Renegotiating masculine identity after prostate cancer treatment. Qual Health Res. 2008;18:1609–1620.
   PubMed Web of Science ®Google Scholar
• Powel LL, Clark JA. The value of the marginalia as an adjunct to structured questionnaires: experiences of men after prostate cancer surgery. Qual Life Res. 2005;14:827–835.
   PubMed Web of Science ®Google Scholar
• Fisher WA, Rosen RC, Eardley I, et al. Sexual experience of female partners of men with erectile dysfunction: the Female Experience of Men’s Attitudes to Life Events and Sexuality (FEMALES) study. J Sex Med. 2005;2:675–684.
   PubMed Web of Science ®Google Scholar
• Rosen R, Goldstein I, Huang X-Y, et al. The Treatment Satisfaction Scale (TSS) is a sensitive measure of treatment effectiveness for both patients and partners: results of a randomized controlled trial with vardenafil. J Sex Med. 2007;4:1009–1021.
   PubMed Web of Science ®Google Scholar
• Martín‐Morales A, Graziottin A, Jaoudé GB, et al. Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double‐blind, placebo‐controlled study. J Sex Med. 2011;8:2831–2840.
   PubMed Web of Science ®Google Scholar
• Albersen M, Shindel AW, Mwamukonda KB, et al. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2010;15:467–480.
   PubMed Web of Science ®Google Scholar
• Hull EM, Hui EK, Chan PK. Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: implications for copulation. Life Sci. 1992;51:1705–1713.
   PubMed Web of Science ®Google Scholar
• Melis MR, Stancampiano R, Gessa GL, et al. Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: site of action in the brain. Neuropsychopharmacology. 1992;6:17–21.
   PubMed Web of Science ®Google Scholar
• Gelez H, Poirier S, Facchinetti P, et al. Neuroanatomical evidence for a role of central melanocortin-4 receptors and oxytocin in the efferent control of the rodent clitoris and vagina. J Sex Med. 2010;7:2056–2067.
   PubMed Web of Science ®Google Scholar
• Van der Ploeg LHT, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci. 2002;99:11381–11386.
   PubMed Web of Science ®Google Scholar
• Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32:379–395.
   PubMed Web of Science ®Google Scholar
• Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6:1232–1247.
   PubMed Web of Science ®Google Scholar
• Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153–165.
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092.
   PubMed Web of Science ®Google Scholar
• Bernat JK, Wittman DA, Hawley ST, et al. Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2016;118:372–378.
   PubMed Web of Science ®Google Scholar
• Carlsson S, Drevin L, Loeb S, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117:E36–E45.
   PubMed Web of Science ®Google Scholar
• Canalichio K, Jaber Y, Wang R. Surgery and hormonal treatment for prostate cancer and sexual function. Transl Androl Urol. 2015;4:103–109.
   PubMed Web of Science ®Google Scholar
• Watson E, Shinkins B, Frith E, et al. Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int. 2016;117:E10–E19.
   PubMed Web of Science ®Google Scholar
• Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions part 1: choosing the right patient at the right time for the right surgery. Eur Urol. 2012;62:261–272.
   PubMed Web of Science ®Google Scholar
• Tal R, Alphs HH, Krebs P, et al. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med. 2009;6:2538–2546.
   PubMed Web of Science ®Google Scholar
• Chung E, Gillman M. Prostate cancer survivorship: a review of erectile dysfunction and penile rehabilitation after prostate cancer therapy. Med J Aust. 2014;200:582–585.
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.
   PubMed Web of Science ®Google Scholar
• Penson DF, Latini DM, Lubeck DP, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care. 2003;26:1093–1099.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397–1404.
   PubMed Web of Science ®Google Scholar
• Pegge NC, Twomey AM, Vaughton K, et al. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med. 2006;23:873–878.
   PubMed Web of Science ®Google Scholar
• Bebb R, Millar A, Brock G. Clinical practice guidelines sexual dysfunction and hypogonadism in men with diabetes diabetes canada clinical practice guidelines expert committee. Can J Diabetes. 2018;42(2018):S228–S233.
   Google Scholar
• Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2009;64:240–255.
   PubMed Web of Science ®Google Scholar
• Bella AJ, Deyoung LX, Al-Numi M, et al. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol. 2007;52:990–1005.
   PubMed Web of Science ®Google Scholar
• Porst H, Gacci M, Büttner H, et al. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol. 2014;65:455–464.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13:465–488.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65:1621–1650.
   PubMed Web of Science ®Google Scholar
• Berner MM, Kriston L, Harms A. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the international index of erectile function in broad-spectrum populations. Int J Impot Res. 2006;18:229–235.
   PubMed Web of Science ®Google Scholar
• Peng Z, Yang L, Dong Q, et al. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: a systematic review and meta-analyses. Urol Int. 2017;99:343–352.
   PubMed Web of Science ®Google Scholar
• Chung E, Broc GB. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011;12:1341–1348.
   PubMed Web of Science ®Google Scholar
• Burns PR, Rosen RC, Dunn M, et al. Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. J Sex Med. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Morales AM, Casillas M, Turbi C. Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature. Int J Impot Res. 2011;23:1–8.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhu L, Zhong J, et al. The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis. Sex Med. 2018;6:185–192.
   Web of Science ®Google Scholar
• Ismail EA, El-Sakka AI. Innovative trends and perspectives for erectile dysfunction treatment: a systematic review. Arab J Urol. 2016;14:84–93.
   PubMed Web of Science ®Google Scholar
• Anderson SG, Romano S, Farzaneh-Far A. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102:1750–1756.
   PubMed Web of Science ®Google Scholar
• Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103:1264–1270.
   PubMed Web of Science ®Google Scholar
• El-Sakka AI. What is the current role of intracavernosal injection in management of erectile dysfunction? Int J Impot Res. 2016;28:88–95.
   PubMed Web of Science ®Google Scholar
• Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130–171.
   PubMed Web of Science ®Google Scholar
• Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7:524–540.
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabe A, Cheliz G, et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol. 1997;157:2132–2134.
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabé A, Chéliz G, et al. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol. 1996;155:913–914.
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008;102:933–937.
   PubMed Web of Science ®Google Scholar
• Fulgham PF, McKenna PH, Hochman HI, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol. 1998;160:2041–2046.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55:109–113.
   PubMed Web of Science ®Google Scholar
• Simonsen U, Comerma-Steffensen S, Andersson K-E. Modulation of dopaminergic pathways to treat erectile dysfunction. Basic Clin Pharmacol Toxicol. 2016;119:63–74.
   PubMed Web of Science ®Google Scholar
• Maclennan KM, Boshier A, Wilton LV, et al. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int. 2006;98:125–131.
   PubMed Web of Science ®Google Scholar
• Capogrosso P, Montorsi F, Salonia A. Expert opinion on investigational drugs Phase I and phase II clinical trials for the treatment of male sexual dysfunction — a systematic review of the literature. Expert Opin Investig Drugs. 2018;00:1–11.
   Google Scholar
• Soebadi MA, Milenkovic U, Weyne E, et al. Stem cells in male sexual dysfunction: are we getting somewhere? Sex Med Rev. 2017;5:222–235.
   PubMed Web of Science ®Google Scholar
• Milenkovic U, Albersen M, Castiglione F. The mechanisms and potential of stem cell therapy for penile fibrosis. Nat Rev Urol. 2018;1. DOI:10.1038/s41585-018-0109-7
   Google Scholar
• Bivalacqua TJ, Hellstrom WJ. Potential application of gene therapy for the treatment of erectile dysfunction. J Androl. 2001;22:183–190.
   PubMed Web of Science ®Google Scholar
• Melman A, Bar-Chama N, McCullough A, et al. h Maxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17:1165–1176.
   PubMed Web of Science ®Google Scholar
• Doh H, Shin CY, Son M, et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res. 2002;25:873–878.
   PubMed Web of Science ®Google Scholar
• Moon DG, Yang DY, Lee CH, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med. 2011;8:2048–2061.
   PubMed Web of Science ®Google Scholar
• Paick J-S, Kim SW, Park YK, et al. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sex Med. 2009;6:3166–3176.
   PubMed Web of Science ®Google Scholar
• Chung BH, Lee JY, Lee SH, et al. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res. 2009;21:122–128.
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60:380–387.
   PubMed Web of Science ®Google Scholar
• Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a Phase II clinical trial. J Sex Med. 2009;6:553–557.
   PubMed Web of Science ®Google Scholar
• Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase iii clinical trial. J Sex Med. 2010;7:1928–1936.
   PubMed Web of Science ®Google Scholar
• Smith WB, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67:768–780.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179:1066–1071.
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Garcia WD, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65:755–759.
   PubMed Web of Science ®Google Scholar
• Chan JSW, Kim DJ, Ahn CH, et al. Clavulanic acid stimulates sexual behaviour in male rats. Eur J Pharmacol. 2009;609:69–73.
   PubMed Web of Science ®Google Scholar
• Albersen M, Linsen L, Tinel H, et al. Synergistic effects of bay 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med. 2013;10:1268–1277.
   PubMed Web of Science ®Google Scholar
• Hannan JL, Albersen M, Kutlu O, et al. Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J Urol. 2013;189:1155–1161.
   PubMed Web of Science ®Google Scholar
• Uvin P, Albersen M, Bollen I, et al. Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. BJU Int. 2017;119:325–332.
   PubMed Web of Science ®Google Scholar
• Saito, A., Inoue M, Kon H, et al. Effectiveness of intraarterial administration of fasudil hydrochloride for preventing symptomatic vasospasm after subarachnoid hemorrhage. Acta Neurochir Suppl. 2015;120:297–301.
   PubMedGoogle Scholar
• Otsuka T, Ibuki C, Suzuki T, et al. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis. 2008;19:105–110.
   PubMed Web of Science ®Google Scholar
• Kun A, Matchkov VV, Stankevicius E, et al. NS11021, a novel opener of large-conductance Ca(2+)-activated K(+) channels, enhances erectile responses in rats. BrJ Pharmacol. 2009;158:1465–1476.
   PubMed Web of Science ®Google Scholar
• Bentzen BH, Olesen S-P, Rã¸Nn LCB, et al. BK channel activators and their therapeutic perspectives. Front Physiol. 2014;5:389.
   PubMed Web of Science ®Google Scholar
• Ralph DJ, Eardley I, Taubel J, et al. Efficacy and safety of MED2005, a topical glyceryl trinitrate formulation, in the treatment of erectile dysfunction: a randomized crossover study. J Sex Med. 2018;15:167–175.
   PubMed Web of Science ®Google Scholar
• Neuzillet Y, Hupertan V, Cour F, et al. A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction. Andrology. 2013;1:223–228.
   PubMed Web of Science ®Google Scholar
• Hupertan V, Neuzillet Y, Stücker O, et al. Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissue. Int J Androl. 2012;35:860–866.
   PubMedGoogle Scholar
• Oottamasathien S, Hotaling JM, Craig JR, et al. Amniotic therapeutic biomaterials in urology: current and future applications. Transl Androl Urol. 2017;6:943–950.
   PubMed Web of Science ®Google Scholar
• Patel VR, Samavedi S, Bates AS, et al. Dehydrated human amnion/chorion membrane allograft nerve wrap around the prostatic neurovascular bundle accelerates early return to continence and potency following robot-assisted radical prostatectomy: propensity score-matched analysis. Eur Urol. 2015;67:977–980.
   PubMed Web of Science ®Google Scholar
• Ogaya-Pinies G, Palayapalam-Ganapathi H, Rogers T, et al. Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis. J Robot Surg. 2018;12:235–243.
   PubMed Web of Science ®Google Scholar
• Epifanova MV, Chalyi ME, Krasnov AO. Investigation of mechanisms of action of growth factors of autologous platelet-rich plasma used to treat erectile dysfunction. Urologiia. 2017; 46–48. http://www.ncbi.nlm.nih.gov/pubmed/28952692
   PubMedGoogle Scholar
• Ding X-G, Li S-W, Zheng X-M, et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl. 2009;11:215–221.
   PubMed Web of Science ®Google Scholar
• Wu -C-C, Wu Y-N, Ho H-O, et al. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med. 2012;9:2838–2848.
   PubMed Web of Science ®Google Scholar
• Wu Y-N, Wu -C-C, Sheu M-T, et al. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med. 2016;10:E294–E304.
   PubMed Web of Science ®Google Scholar
• Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59:61.
   PubMed Web of Science ®Google Scholar
• Marks AR. Cellular functions of immunophilins. Physiol Rev. 1996;76:631–649.
   PubMed Web of Science ®Google Scholar
• Steiner JP, Dawson TM, Fotuhi M, et al. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature. 1992;358:584–587.
   PubMed Web of Science ®Google Scholar
• Gold BG, Katoh K, Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci. 1995;15:7509–7516.
   PubMed Web of Science ®Google Scholar
• Gold BG, Storm-Dickerson T, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci. 1994;6:287–296.
   PubMed Web of Science ®Google Scholar
• Bavetta S, Hamlyn PJ, Burnstock G, et al. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol. 1999;158:382–393.
   PubMed Web of Science ®Google Scholar
• Mulhall J, Klein E, Slawin K, et al. Tacrolimus (fk506) as a neuromodulator in the radical prostatectomy population: a multicenter, double-blind, randomized, placebo-controlled trial. J Urol. 2010;183:e530–e531.
   Web of Science ®Google Scholar
• Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A. 2003;100:6741–6746.
   PubMed Web of Science ®Google Scholar
• Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J. 2001;15:1804–1806.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Levine P, Khoury JC. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647–e656.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Minnerup J. Promoting recovery from ischemic stroke. Expert Rev Neurother. 2016;16:173–186.
   PubMed Web of Science ®Google Scholar
• Liu T, Allaf ME, Lagoda G, et al. Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis. BJU Int. 2007;100:1103–1106.
   PubMed Web of Science ®Google Scholar
• Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol. 2005;174:2060–2064.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Allaf ME, Bivalacqua TJ. Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. J Sex Med. 2008;5:2392–2398.
   PubMed Web of Science ®Google Scholar
• Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–29.
   PubMed Web of Science ®Google Scholar
• Ghanem H, Raheem AA, AbdelRahman IFS, et al. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6:135–142.
   PubMedGoogle Scholar
• Giuliano F, Brock G. Botox for erectile dysfunction. J Sex Med. 2017;14:177–178.
   PubMedGoogle Scholar
• Ghanem H, Soliman I, AbdulHamid M, et al. PS-08-016 Can intracavernosal botulinum toxin injection salvage vascular erectile dysfunction patients not responding to oral and intracavernous therapy? A pilot study. J Sex Med. 2016;13:S116.
   Web of Science ®Google Scholar
• Gur S, Peak T, Yafi FA, et al. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction? BJU Int. 2016;118:464–474.
   PubMed Web of Science ®Google Scholar
• Van Driel MF. Physiology of penile erection-a brief history of the scientific understanding up till the eighties of the 20th century. Sex Med. 2015;3:349–357.
   PubMed Web of Science ®Google Scholar